"Vulvar cancer (VC) is a rare disease, usually diagnosed in a stage still amenable of potentially curative treatments, including surgery and\/or radiation therapy with or without chemotherapy. Several patients however present at diagnosis with metastatic disease and another 30–50% will relapse. Prognosis of metastatic or recurrent disease not amenable to a salvage surgery or radiotherapy is very poor. Evidences about efficacy of chemotherapy in this setting are few and its role remains yet unclear. At present there is no standard treatment for advanced VC and patients are usually treated with schedules adopted for chemoradiation or extrapolated from cervical cancer. We report our experience using a cisplatin-gemcitabine regimen in two cases of metastatic squamous cell VC. No response was obtained with this schedule. No other data are available in the literature about the choice of a cisplatin-gemcitabine regimen in this patient subset. The paucity of evidence about the role of palliative chemotherapy in metastatic VC justifies any effort in order to implement knowledge. For this reason we think interesting to report also a negative experience. It is not possible for us to conclude that this chemotherapy is unable to provide any benefit in a bigger sample of patients; anyway we think that new agents, rather than combinations of older drugs, could hopefully provide more benefit."

Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases / Santeufemia, Da; Capobianco, Giampiero; Lo Re, G; Miolo, Gm; Fadda, Gm; Cherchi, Pier Luigi; Tumolo, S.. - In: EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. - ISSN 0392-2936. - 33:4(2012), pp. 421-422.

Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases.

CAPOBIANCO, Giampiero;CHERCHI, Pier Luigi;
2012-01-01

Abstract

"Vulvar cancer (VC) is a rare disease, usually diagnosed in a stage still amenable of potentially curative treatments, including surgery and\/or radiation therapy with or without chemotherapy. Several patients however present at diagnosis with metastatic disease and another 30–50% will relapse. Prognosis of metastatic or recurrent disease not amenable to a salvage surgery or radiotherapy is very poor. Evidences about efficacy of chemotherapy in this setting are few and its role remains yet unclear. At present there is no standard treatment for advanced VC and patients are usually treated with schedules adopted for chemoradiation or extrapolated from cervical cancer. We report our experience using a cisplatin-gemcitabine regimen in two cases of metastatic squamous cell VC. No response was obtained with this schedule. No other data are available in the literature about the choice of a cisplatin-gemcitabine regimen in this patient subset. The paucity of evidence about the role of palliative chemotherapy in metastatic VC justifies any effort in order to implement knowledge. For this reason we think interesting to report also a negative experience. It is not possible for us to conclude that this chemotherapy is unable to provide any benefit in a bigger sample of patients; anyway we think that new agents, rather than combinations of older drugs, could hopefully provide more benefit."
2012
Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases / Santeufemia, Da; Capobianco, Giampiero; Lo Re, G; Miolo, Gm; Fadda, Gm; Cherchi, Pier Luigi; Tumolo, S.. - In: EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. - ISSN 0392-2936. - 33:4(2012), pp. 421-422.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/155552
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact